Safety, tolerability and immunogenicity of low dose Haemophilus influenzae type b conjugated to the outer membrane protein complex of Neisseria meningitidis group B.
Infants vaccinated with three doses followed by a booster of either 1.0 microg of Haemophilus influenzae type b conjugated to the outer membrane protein complex of Neisseria meningitidis group B or H. influenzae 10-microg oligosaccharide vaccine conjugated to 25 microg mutant toxin (CRM197) isolated from Corynebacterium diphtheriae had protective antipolyribosylribitol phosphate concentrations.
Anderson
Edwin L
EL
Saint Louis University Health Sciences Center Division of Infectious Disease and Immunology, St Louis, MO, USA.
Frey
Sharon
S
Geldmacher
Kathy
K
Radley
David
D
Lee
Ann
A
Donnelly
John
J
Mendelman
Paul M
PM
Dargan
Jennifer M
JM
Kaplan
Karen M
KM
D000917:Antibody Formation; D001425:Bacterial Outer Membrane Proteins; D004305:Dose-Response Relationship, Drug; D005260:Female; D006192:Haemophilus Infections / Q000276:immunology / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D019741:Haemophilus influenzae type b / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D007223:Infant; D008297:Male; D009345:Neisseria meningitidis / Q000737:chemistry / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology*
D001425:Bacterial Outer Membrane Proteins; D018073:Haemophilus Vaccines; D018074:Vaccines, Conjugate